The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We asses...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Parmar, Kalindi, Kochupurakkal, Bose S., Lazaro, Jean-Bernard, Wang, Zhigang C., Palakurthi, Sangeetha, Kirschmeier, Paul T., Yang, Chunyu, Sambel, Larissa A., Farkkila, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E., Zou, Lee, Do, Khanh T., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Liu, Joyce F., D’Andrea, Alan D., Shapiro, Geoffrey I.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801076/
https://ncbi.nlm.nih.gov/pubmed/31409614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0448
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki